KR102527052B1 - 항-kras-g12d t 세포 수용체 - Google Patents

항-kras-g12d t 세포 수용체 Download PDF

Info

Publication number
KR102527052B1
KR102527052B1 KR1020197005837A KR20197005837A KR102527052B1 KR 102527052 B1 KR102527052 B1 KR 102527052B1 KR 1020197005837 A KR1020197005837 A KR 1020197005837A KR 20197005837 A KR20197005837 A KR 20197005837A KR 102527052 B1 KR102527052 B1 KR 102527052B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
amino acids
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197005837A
Other languages
English (en)
Korean (ko)
Other versions
KR20190064566A (ko
Inventor
에릭 트란
용-천 루
안나 파세토
폴 에프 로빈스
스티븐 에이 로젠버그
질리 정
Original Assignee
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Publication of KR20190064566A publication Critical patent/KR20190064566A/ko
Application granted granted Critical
Publication of KR102527052B1 publication Critical patent/KR102527052B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
KR1020197005837A 2016-08-02 2017-07-31 항-kras-g12d t 세포 수용체 Active KR102527052B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02
US62/369,883 2016-08-02
PCT/US2017/044615 WO2018026691A1 (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Publications (2)

Publication Number Publication Date
KR20190064566A KR20190064566A (ko) 2019-06-10
KR102527052B1 true KR102527052B1 (ko) 2023-04-27

Family

ID=59564253

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005837A Active KR102527052B1 (ko) 2016-08-02 2017-07-31 항-kras-g12d t 세포 수용체

Country Status (20)

Country Link
US (6) US10611816B2 (enExample)
EP (2) EP3494133B1 (enExample)
JP (4) JP6993402B2 (enExample)
KR (1) KR102527052B1 (enExample)
CN (2) CN118063591A (enExample)
AU (2) AU2017306038B2 (enExample)
CA (1) CA3032870A1 (enExample)
DK (1) DK3494133T3 (enExample)
ES (1) ES2928051T3 (enExample)
HR (1) HRP20221183T1 (enExample)
HU (1) HUE060121T2 (enExample)
IL (2) IL264425B2 (enExample)
LT (1) LT3494133T (enExample)
PL (1) PL3494133T3 (enExample)
PT (1) PT3494133T (enExample)
RS (1) RS63615B1 (enExample)
SG (2) SG11201900654QA (enExample)
SI (1) SI3494133T1 (enExample)
SM (1) SMT202200379T1 (enExample)
WO (1) WO2018026691A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264425B2 (en) * 2016-08-02 2023-09-01 Us Secretary Department Of Health And Human Services t cell receptors against kras-g20
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CR20240019A (es) 2017-09-20 2024-02-15 Us Health RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150)
EP4269595A3 (en) 2017-10-05 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selectively expanding cells expressing a tcr with a murine constant region
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
SG11202108039QA (en) * 2019-01-25 2021-08-30 Univ Pennsylvania Compositions and methods for targeting mutant ras
WO2020172332A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术(广东)有限公司 一种识别Kras G12V的高亲和力TCR
CA3160468A1 (en) * 2019-11-05 2021-05-14 Board Of Regents, The University Of Texas System Hla restricted hormad1 t cell receptors and uses thereof
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
CN116034113A (zh) * 2019-12-30 2023-04-28 华夏英泰(北京)生物技术有限公司 一种增强型t细胞受体star及其应用
AU2021310213A1 (en) * 2020-07-13 2023-03-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted DRB T cell receptors against ras with g12d mutation
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
WO2022109220A1 (en) * 2020-11-20 2022-05-27 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
AU2021388167A1 (en) * 2020-11-25 2023-07-06 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
US20240175047A1 (en) 2021-02-25 2024-05-30 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
EP4558152A2 (en) * 2022-07-22 2025-05-28 Board of Regents, The University of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270B (zh) * 2022-09-29 2025-04-25 广州医科大学 一种t细胞受体(tcr)及其用途
EP4633665A2 (en) * 2022-12-13 2025-10-22 BioNTech US Inc. T cell receptor constructs and uses thereof
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048593A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
BR112013006718B1 (pt) 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT2755997T (pt) * 2011-09-15 2018-10-30 Us Health Recetores de célula t que reconhecem mage restrito a hlaa1 ou hla-cw7
WO2013081188A1 (ja) * 2011-11-30 2013-06-06 独立行政法人国立がん研究センター 誘導悪性幹細胞
KR20160013049A (ko) * 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
CA2968399A1 (en) 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
IL264425B2 (en) * 2016-08-02 2023-09-01 Us Secretary Department Of Health And Human Services t cell receptors against kras-g20
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048593A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
New England Journal of Medicine 375(23):2255-2262(2016.12.08.)

Also Published As

Publication number Publication date
US20250340611A1 (en) 2025-11-06
US11208456B2 (en) 2021-12-28
US12391742B2 (en) 2025-08-19
US11897933B2 (en) 2024-02-13
SG10201913959WA (en) 2020-03-30
US20210300988A1 (en) 2021-09-30
CN118063591A (zh) 2024-05-24
JP6993402B2 (ja) 2022-02-03
HUE060121T2 (hu) 2023-01-28
DK3494133T3 (da) 2022-09-19
EP4159751A1 (en) 2023-04-05
SI3494133T1 (sl) 2022-11-30
US20200247869A1 (en) 2020-08-06
US20240209059A1 (en) 2024-06-27
RS63615B1 (sr) 2022-10-31
CN109790211B (zh) 2024-03-26
KR20190064566A (ko) 2019-06-10
EP3494133A1 (en) 2019-06-12
PT3494133T (pt) 2022-09-28
WO2018026691A1 (en) 2018-02-08
AU2023233125B2 (en) 2025-10-16
AU2023233125A1 (en) 2023-10-12
CN109790211A (zh) 2019-05-21
EP3494133B1 (en) 2022-07-06
US11840561B2 (en) 2023-12-12
JP2019527555A (ja) 2019-10-03
JP2025090690A (ja) 2025-06-17
AU2017306038A1 (en) 2019-02-14
JP7413338B2 (ja) 2024-01-15
IL264425A (enExample) 2019-03-31
SG11201900654QA (en) 2019-02-27
IL301894B2 (en) 2025-02-01
IL264425B1 (en) 2023-05-01
JP2024045139A (ja) 2024-04-02
US20190177395A1 (en) 2019-06-13
US10611816B2 (en) 2020-04-07
IL301894B1 (en) 2024-10-01
US20220089677A1 (en) 2022-03-24
LT3494133T (lt) 2022-12-12
IL264425B2 (en) 2023-09-01
AU2017306038B2 (en) 2023-06-22
CA3032870A1 (en) 2018-02-08
HRP20221183T1 (hr) 2022-12-09
JP2022050400A (ja) 2022-03-30
ES2928051T3 (es) 2022-11-15
IL301894A (en) 2023-06-01
JP7649370B2 (ja) 2025-03-19
PL3494133T3 (pl) 2022-11-21
SMT202200379T1 (it) 2022-11-18

Similar Documents

Publication Publication Date Title
US12391742B2 (en) Anti-KRAS-G12D T cell receptors
US20230406904A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
HK40009637B (en) Anti-kras-g12d t cell receptors
HK40009637A (en) Anti-kras-g12d t cell receptors
HK40008470A (en) Anti-kras-g12d t cell receptors
HK40008470B (zh) 抗kras-g12d t细胞受体
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200731

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220829

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230127

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230425

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230425

End annual number: 3

Start annual number: 1

PG1601 Publication of registration